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Abstract
Genes involved in the carcinogenetic mechanisms underlying malignant pleural mesothelioma (MPM) are still poorly
characterized. So far, mesothelin (MSLN) has aroused the most interest. It encodes for a membrane glycoprotein, frequently
over-expressed in various malignancies such as MPM, and ovarian and pancreatic cancers. It has been proposed as a
diagnostic and immunotherapeutic target with promising results. However, an alternative therapeutic approach seems to
rise, whereby synthetic molecules, such as antisense oligonucleotides, could be used to inhibit MSLN activity. To date, such
a gene-level inhibition has been attempted in two studies only, both on pancreatic and ovarian carcinoma cell lines, with
the use of silencing RNA approaches. With regard to MPM, only one cell line (H2373) has been employed to study the effects
of MSLN depletion. Indeed, the knowledge on the role of MSLN in MPM needs expanding. Accordingly, we investigated the
expression of MSLN in a panel of three MPM cell lines, i.e. NCI-H28, Mero-14, and IstMes2; one non-MPM cell line was used as
reference (Met5A). MSLN knock-down experiments on MSLN-overexpressing cells were also performed through silencing
RNA (siRNA) to verify whether previous findings could be generalized to a different set of cell cultures. In agreement with
previous studies, transient MSLN-silencing caused decreased proliferation rate and reduced invasive capacity and sphere
formation in MSLN-overexpressing Mero-14 cells. Moreover, MSLN-siRNA combined with cisplatin, triggered a marked
increase in apoptosis and a decrease in proliferation as compared to cells treated with each agent alone, thereby suggesting
a sensitizing effect of siRNA towards cisplatin. In summary, our findings confirm that MSLN should be considered a key
molecular target for novel gene-based targeted therapies of cancer.
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Introduction
Malignant pleural mesothelioma (MPM) is a cancer of the
pleural cavity triggered by asbestos exposure. Patients with MPM
have a poor prognosis, with overall survival typically ranging
between 6 and 13 months. The carcinogenetic mechanisms
underlying MPM and the genes involved are still poorly
characterized although, so far, MSLN has aroused the most
interest. The human MSLN gene encodes a ,71 kDa precursor
protein of 622 amino acids. The precursor is processed by a
removal of 33 N-terminal residues. Moreover, the C-terminal
residues departing from Ser598 are replaced with glycosyl-
phosphatidyl-inositol (GPI) facilitating the anchoring of the
peptide to the cell membrane. Then, the precursor is cleaved at
Arg295 by the endoprotease furin into a ,31 kDa soluble peptide
called ‘‘megakaryocyte potentiating factor’’ (from aminoacid Ser34
to Arg286) [1] and a ,40 kDa GPI-anchored membrane-bound
glycoprotein (mature mesothelin, MSLN, starting from Glu296)
[2,3,4]. It was found that MSLN is present at low levels in a
restricted set of normal adult tissues, including the mesothelium,
but it is overexpressed aberrantly by several cancers, such as
MPM, and pancreatic (PC) and ovarian carcinomas (OC) [5,6].
Moreover, a soluble form of MSLN (soluble mesothelin related
peptide, SMRP) is known, lacking the C-terminal GPI-membrane
anchor binding segment [7]. Interestingly, the levels of SMRP are
elevated in the sera of MPM, PC, or OC patients but not in
patients with other types of cancer or inflammatory diseases, or in
healthy controls [8,9,10]. Unfortunately, since MSLN knock-out
mice did not exhibit any adverse pathology, the exact function of
MSLN remains unclear [11]. Recent studies highlighted the
possible mechanisms by which MSLN could play an active role in
cancer progression; it was shown to interact with MUC16 [12],
and to activate the p38 pathway, leading to the selective induction
of matrix metalloproteinase (MMP)-7 [13]. MSLN could also
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increase cancer cell survival and proliferation via the activation of
the NF-kB signaling pathway [14]. Finally, it was suggested that
MSLN could exert its role in the malignant transformation of
human cells, through the b-catenin pathway, an important
molecule for the epithelial-mesenchymal transition [15].
For all these reasons, MSLN was considered a good target for
immunotherapeutic strategies. In fact, it was used to deliver
immunotoxins to specific cancer cells [16,17,18,19,20,21], or, such
as for the case of the monoclonal antibody MORAb-009, to arrest
cancer progression by direct inhibition (e.g. disrupting the
interaction with MUC16) [22]. Although the use of monoclonal
antibodies could provide several advantages (indeed MORAb-009
is currently under clinical trial), target-specific drugs or novel
inhibitors (such as antisense oligonucleotides) acting at gene-level
could be an alternative for complete inhibition.
To date, direct inhibition of mesothelin with non-immune
strategies has been attempted in a very limited number of studies,
using silencing RNA (siRNA) approaches. One study, on the Eker
(Tsc2 mutant) rat model of hereditary renal cancer, showed tumor
growth inhibition following the use of siRNA microspheres
designed against Erc, which is considered the rat homologue of
MSLN [23]. On human cells, one study was carried out on PC cell
lines AsPC-1, Capan-1, and Capan-2 [24], whereas another one
was performed on cell lines from PC (Miapaca2 and Panc-1) and
OC (Skov3 and Ovcar-5) [25]. Overall, MSLN depletion
significantly hampered proliferation and colony-forming capabil-
ity. A decreased viability and invasiveness of PC and OC cell lines
were also observed [25]. Moreover, the expression of bcl-2
decreased whilst that of PUMA and Bax increased; at the same
time, the activity of caspase-3 increased. Consistently with these
observations, an increased apoptotic rate was observed in PC cells
and the data were conversely corroborated when MSLN was
ectopically over-expressed in HPAC cells, a PC cell line poorly
expressing MSLN [24]. With regard to MPM, so far only one cell
line (H2373) has been employed to study the effects of MSLN
depletion [25]. Indeed, the knowledge on the role of MSLN in
MPM should be expanded. Accordingly we investigated the
expression of MSLN in a panel of three MPM cell lines, i.e. NCI-
H28, Mero-14, and IstMes2; one non-MPM cell line was used as
reference (Met5A). We then performed MSLN knock-down
experiments in highly expressing MSLN cells, through gene
silencing (using silencing RNA, siRNA) to verify whether previous
findings could be generalized to a different set of cell cultures,
further corroborating the importance of MSLN in the biology of
MPM.
Materials and Methods
Cell cultures
Three mesothelioma cell lines (Mero-14, IstMes2, and NCI-
H28) and one mesothelial non-MPM immortalized cell line
(Met5A) were used. Mero-14 [26], and IstMes2 [27] mesothelioma
cells had been kindly donated by the Istituto Tumori of Genova
(National Research Council, Genoa, Italy). The Met5A mesothe-
lial cells and the NCI-H28 mesothelioma cells had been purchased
from the ATCC (American Type Culture Collection) and kindly
donated by collaborators of the Pharmaceutical Department of the
University of Pisa. Met5A, Mero-14, and NCI-H28 cell lines were
verified for their identity, by analyzing the genetic markers
reported in the certification. IstMes2 is a locally established cell
line. Mero-14, and IstMes2 were cultured in DMEM medium
(Lonza, Basel, Switzerland). The NCI-H28 cell line was grown in
RPMI 1640 medium (Gibco, Life Technologies, Monza, Italy).
The Met5A cell line was grown in Medium199 with HEPES (Life
Technologies, Monza, Italy) supplemented with 3.3 nM epidermal
growth factor (EGF, Life Technologies, Monza, Italy), 400 nM
hydrocortisone (Sigma Aldrich Corp. St Louis, MO, USA), and
870 nM insulin (Life Technologies, Monza, Italy). All the cell lines
were cultured with supplement of 10% fetal bovine serum (Sigma
Aldrich Corp. St Louis, MO, USA), and 1% Pen-Strep (Lonza,
Basel, Switzerland), and maintained at 37uC in a 5% CO2–
humidified atmosphere (Forma* 311 Direct Heat CO2 Incubator,
Thermo Scientific, Waltham, MA, USA).
RNA isolation and cDNA synthesis
Total RNA was isolated from each cell line with Rneasy Mini
kit (Qiagen MI, Italy), according to the standard protocol. In order
to remove possible contaminating genomic DNA, the extracted
RNA was treated with DNAse buffer (Sigma Aldrich Corp. St
Louis, MO, USA). Concentration and purity of cleaned-up RNA
were determined with a spectrophotometer (SmartSpec 3000, Bio-
Rad Laboratories, Hercules, CA). The integrity of total RNA was
verified by electrophoresis on ethidium bromide agarose gel,
inspecting the 18S and 28S ribosomal RNA bands. Reverse
transcription (RT) was performed with the iSCRIPT cDNA Synthesis
Kit using 1mg of total RNA in a final volume of 20ml (Bio-Rad
Laboratories, Hercules, CA).
Quantitative Real-Time PCR (RT-qPCR)
Pre-designed TaqMan probes (Life Technologies, Monza, Italy)
were employed. For the TaqMan assay, the reaction mixture
consisted of 2 ml of cDNA template, 7 ml of deionized H2O, 1 ml of
specific TaqMan Assay probe and primer mixture, and 10 ml of
TaqManH Gene Expression Master Mix (Life Technologies,
Monza, Italy). The thermal cycling conditions were: 15 min at
95uC followed by 15 s at 95uC and 60 s at 60uC (40 cycles).
TaqMan ID assays are reported in Table S1. Seven housekeeping
genes, GAPDH, HPRT1, B2M, RPLP0, TBP, GUSB and PPIA, were
tested for stability, to be used as reference. The three most stable
genes (RPLP0, HPRT, and TBP) were determined based on the
average M and the pair-wise variation values, calculated with the
tool geNorm [28].
Chemicals
The drugs were dissolved in DMSO at the final concentration of
10 mM. Imatinib was purchased from Cayman Chemical
(Michigan, USA) and used in the range of 5–25 mM; Gemcitabine
was obtained from Sigma Aldrich Corp. (St Louis, MO, USA) and
used in the range of 1–10 mM; Cisplatin, kindly donated by Prof.
Justin Stebbing (Imperial College, London), was used in the range
1–25 mM. The following antibodies were used: MSLN mouse
monoclonal (Santa Cruz); b-actin mouse monoclonal (Abcam),
p53 mouse monoclonal (Santa Cruz); pERK, mouse polyclonal
(Abcam); PARP rabbit polyclonal (Cell Signaling); pAKT rabbit
polyclonal (Abcam); ERK1-2 rabbit polyclonal (Abcam); Second-
ary HRP (horseradish peroxidase)-conjugated goat anti-rabbit IgG
and goat antimouse IgG antibodies were from GE Healthcare.
The expression plasmid pcDNA3.1 encoding for MSLN (aa 360-
2230) was kindly donated by Dr. Uehara (Kansai Medical
University, Japan); the empty vector pcDNA3.1, employed as
control, was donated by Dr. Giamas (Imperial College, London).
siRNA and plasmid transfections
siMSLN-1 and-2 were purchased from Qiagen (Qiagen, S.p.A,
Milano, Italy). The ‘‘AllStars Negative Control siRNA’’
(SI03650318) was used as non-targeting control (siRNA-Ctrl).
siRNA oligonucleotides were re-suspended in the provided buffer
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at a final stock concentration of 20 mM. siRNA transfection was
performed with the HiPerfect transfection reagent (Qiagen, S.p.A,
Milano, Italy), according to the manufacturer’s instructions.
Plasmid transfections were performed using the FuGENEH
Transfection Reagent (Promega Corp. Madison, Wisc., USA) in
penicillin/streptomicine-free DMEM for 24 hs according to
manufacturer’s instructions.
Protein extraction and Western Blotting
Cell pellets were suspended in ice-cold RIPA buffer containing
protease and phosphatase inhibitors (Sigma Aldrich Corp. St
Louis, MO, USA). The extracts were then clarified by centrifu-
gation at 15000 rpm for 15 min at 4uC, and the protein
concentration was determined with the Bradford reagent (Bio-Rad
Laboratories, Hercules, CA) and spectrophotometric analysis.
Lysates were incubated in 5x sodium dodecyl sulfate (SDS) sample
buffer (5 min, 95uC). An amount of 10-30 mg of proteins for each
sample was loaded onto 8–15% SDS polyacrylamide gel. Proteins
were then transferred onto a nitrocellulose membrane. The
membrane was blocked for 1h with non-fat dry milk in TBS
containing 0.05% Tween 20, washed, and successively incubated
with different primary antibodies for 12h at 4uC. The membranes
were then washed three times for 10 min and incubated with the
HRP-conjugated secondary antibody for 1h at room temperature
(RT). After a thorough washing, the blot was exposed to ECL (GE
Healthcare, NJ) followed by autoradiography. The intensity of the
bands was quantified using Image J software (NIH, Bethesda,
MD).
Sulphorhodamine (SRB) assay
Cells were seeded in 96 well plates at a density of 36103. The
next day, (day 0), one plate was assessed. The remaining plates
were tested at 2-day intervals for a total of 6–8 days. Cells were
fixed with 100 mL per well of ice-cold 40% (vol/vol) TCA (Sigma
Aldrich Corp. St Louis, MO, USA) gently added on top of the
medium overlaying the cells. The plates were then incubated for
60 min at 4uC. Wells were rinsed five times with tap water and
then stained with 0.4% SRB solution (100 ml stain/well; Sigma
Aldrich Corp. St Louis, MO, USA) for 30 min at RT. After
staining, SRB solution was removed, unbound dye was removed
by washing five times with 1% acetic acid solution and left to air
dry. The bound SRB dye was then solubilized by adding
unbuffered Tris-base solution (100 ml/well), and plates were
placed on a plate shaker for 10 min at room temperature. Plates
were then read at OD 492 nm, using a microplate reader.
3D Overlay Culture on Matrigel
Thawed Matrigel (BD Bioscience) in a volume of 70 ml/well was
added into each of the wells of the eight-well glass slide chambers
(Thermo Scientific), and spread to form a 1-mm thick bed.
Matrigel was left to solidify at 37uC for 15 min. Then, cells
(16103/well) were plated in medium containing 2% Matrigel and
allowed to grow in a 5% CO2 humidified incubator at 37uC.
Flow cytometry (FACS)
After treatments, 16105 cells were collected, washed in
phosphate-buffered saline (PBS), pelleted by centrifugation and
fixed in 70% ethanol. Immediately prior to staining, the cells were
washed twice in PBS and suspended in PBS containing 50 mg/ml
of RNAse A (Qiagen, S.p.A, Milano, Italy). The cells were stained
with propidium iodide (final concentration 100 mg/ml) for at least
1 h at 4uC and analyzed using a LSR II flow cytometer (BD
Biosciences). The percentage of cells in subG1, G0/G1, S and
G2/M phases were determined from .10,000 cells using the
FACSDiva 6.0 software (BD Biosciences).
Caspase - GloH 3/7 assay
Caspase-3/7 activation was measured using the Caspase-Glo 3/
7 Luminescence Assay (Promega Corp. Madison, Wisc., USA)
according to the manufacturer’s instructions. In a 6 well plate
36105 cells were incubated. The day after, the cells were treated
with siRNAs, both with and without drugs, for 48 h. Then, the
cells were collected by trypsinization, and approximately 156103
cells were transferred in a 96-well white plate. Caspase-3/7-Glo
reagent was added, and the samples were incubated at 37uC for 1
h. The luminescence that is proportional to the caspase 3/7
activities was determined by luminometer (Tecan Sunrise, Austria
GMBH).
Transwell Cell Invasion Assay
About 56104 cells in 200 ml of a-MEM (Gibco, Life Technol-
ogies, Monza, Italy) were plated in the Matrigel-coated upper
Figure 1. Expression levels of MSLN in human MPM cell lines
and Met5A. A. RT-qPCR showing the mRNA expression levels of MSLN
measured on MPM cell lines and related to Met5A cells (set to 1). RPLP0,
HPRT, and TBP were used for normalization. Error bars show the
standard error of the mean (SEM) from three independent experiments,
each performed in triplicate. Mero-14 cells showed the highest
expression levels of MSLN (P = 0.02). B. The protein levels of MSLN in
Met5A, Mero-14, IstMes2, and NCI-H28 cells. b-actin was used as
reference. The protein levels were confirmed by two independent
experiments. MSLN is shown as a band at 40 kDa. C. RT-qPCR showing
the endogenous mRNA expression levels of MSLN in Mero-14 cells,
related to their own siCtrl (set to 1). RPLP0, HPRT, and TBP were used for
normalization. Error bars are SEM, from three independent experiments,
each performed in triplicate. The siRNA chosen for the analysis is:
siMSLN-1 (40 nM; *P = 0.002) active on Mero-14 cells. D. Protein levels of
MSLN (shown as a band at 40 kDa) after depletion with siMSLN-1 and -2
(40 nM). b-actin was used as reference. The protein levels were
confirmed by three independent experiments.
doi:10.1371/journal.pone.0085935.g001
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chambers of the 24-well Transwell invasion assay plate (Corning,
NY 14831 USA). Plates were incubated at 37uC for 48 h. Cells in
the lower chamber (including those attached to the lower surface
of the membrane) were fixed in 4% paraformaldehyde (VWR,
Milan Italy), stained with DAPI (Lonza, Basel, Switzerland), and
counted with fluorescence microscope (Metamorph – Axiovert
microscope).
Wound-Healing Assay
About 256103 cells were seeded in a 12-well plate and, after 24
h, transfected with siMSLN-1. A linear scratch in the confluent cell
monolayer was made with a sterile pipette tip after 12 h (time
optimized following preliminary trials) following siRNA transfec-
tions. Then, cells were rinsed and incubated in full medium.
Finally, cells were inspected and fixed with paraformaldehyde after
36 h, following the scratch. Cells were stained with crystal violet
0.1%solution (dissolved in 20% ethanol) to enhance contrast and
photographed with a phase-contrast microscope at 10X magnifi-
cation. The migration was then evaluated on the images, and
measured with Image J software.
Statistical analyses
The measurements of gene expression performed on cell lines,
and the results obtained from the in vitro assays were statistically
evaluated using a two-tailed Student’s t-test. The effects of the
combination of treatments (drugs +/– siRNAs) were evaluated
with a multifactor analysis of variance (MANOVA) model. The
statistics were performed with the software R (http://www.r-
project.org/) and Statgraphics Centurion XV (StatPoint, Inc.).
Results
MSLN expression in MPM cell lines
The expression level of MSLN was screened in Mero-14,
IstMes2, and NCI-H28 human MPM cell lines. Met5A, a non-
malignant immortalized cell line, was also screened and used as
reference. The expression of MSLN mRNA in Mero-14 cells was
higher than in Met5A (Figure 1A). Western blotting supported
these data, showing high MSLN levels in Mero-14 cells (Figure 1B)
and low levels in Met5A. Similar to mRNA expression, IstMes2
had lower levels of MSLN than Met5A.No levels of MSLN were
observed for NCI-H28. Thus, two different silencing-RNAs
(siRNAs) were assayed: siMSLN-1 and siMSLN-2 for MSLN in
Mero-14 cells, (Table S2; Figure 1C). For further experiments,
Figure 2. Role of MSLN in cellular growth. A. SRB proliferation assay in Mero-14 cells treated with 40 nM of the siCtrl or siMSLN-1 (*P = ,1024).
Error bars represent SEM of three independent experiments, each performed in quadruplicate. B. Western blotting analysis of MSLN, p-AKT, p-ERK,
and ERK1-2, on Mero-14 cells treated with siCtrl, or siMSLN-1, and on NCI-H28 cells transfected with an empty vector (pcDNA3.1) or a plasmid
overexpressing MSLN (pcDNA3.1-MSLN). b-actin was used as reference. The protein levels were confirmed with three independent experiments. C.
The picture represents the phase contrast microscopy of Mero-14 cells cultured in 3D Matrigel-overlay chambers after silencing of MSLN (siMSLN-1 at
40 nM). Magnification 10X. Two different experiments were performed, each in triplicate. The percentages of Mero-14 cells classified according to the
dimensions of the spheres following treatments with siCtrl or siMSLN-1 in 3D Matrigel-overlay chambers were also reported. Legend to figure 2:
Gray line = cells treated with siMSLN-1; Dark line = cells treated with siCtrl.
doi:10.1371/journal.pone.0085935.g002
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siMSLN-1 was employed given its better performance in gene
silencing (.95% for siMSLN-1 Figure 1D).
Role of MSLN in cellular growth
The effect of MSLN silencing on cellular growth was evaluated
by performing two different assays: the SRB assay and the 3D
Matrigel-overlay model. The first facilitates the assessment of the
number of cells grown in a bi-dimensional context at a given time
[29], whilst the latter, facilitates the evaluation of the dimension
and shape of spheroids formed in a three-dimensional context.
Following the administration of siMSLN-1, a significant reduction
(p , 0.05) in the proliferation rate was observed for Mero-14 cells,
starting from the third day of treatment, as compared to cells
treated with control siRNA (siCtrl), reaching a 86% decrease at
day 6 (Figure 2A). This result was also corroborated by a reduced
expression of the phosphorylated forms of AKT and ERK, pAKT
and pERK being markers of proliferation [30] (Figure 2B). When
MSLN was transiently over-expressed in the non-MSLN expressing
NCI-H28 cells, increased levels of pAKT and pERK were
observed, confirming a link between MSLN expression and
proliferation (Figure 2B). The silencing of MSLN in Mero-14 cells
was also associated with smaller and uniform spheres (mean =
34.4 mm63.11), as compared to the cells treated with siCtrl (mean
= 52.5 mm, 67.65, p,1026). About 72.5% of siCtrl-treated
spheres and only 22.5% of siMSLN-1-treated spheres measured .
40 mm (Figure 2C). Thus, Mero-14 cells following MSLN silencing
showed a low proliferation rate and a reduced capacity of forming
spheroids.
Role of MSLN in cell cycle progression and apoptosis
To examine the effects of MSLN silencing on cell cycle
progression, Mero-14 cells were treated with siCtrl and siMSLN-
1, for 72 h and analyzed with flow cytometry. A statistically
significant decreased share of Mero-14 cells in S+G2+M-phases
was observed following MSLN silencing as compared to controls
(Figure 3). The reduction (standardized for siCtrl) was approxi-
mately by 25%. Measured at 48 h after siRNA transfection, the
Mero-14 cell line did not show any changes in the activities of
apoptosis markers: caspase-3 and -7.
Role of MSLN in migration and invasion
The effect of gene silencing on cellular migration was evaluated
using the wound-healing assay (assessing the repopulation of a
scratched area in a plate) [31].The invasiveness was measured
using the trans-well assay (assessing the number of cells passing
through the pores of the membrane) [32]. No statistically
significant differences in migration parameters were observed in
Mero-14 following the siRNA treatments (Figure 4A). However,
Mero-14 cells showed a statistically significant reduced invasion, as
compared to controls, at 48 h after MSLN silencing (Figure 4B).
Role of MSLN in cellular growth following treatments
with chemotherapeutic drugs
After 6 days of treatment, cisplatin used as a single agent caused
a 26% reduction (not statistically significant) in the proliferation
rate of Mero-14 cells. Then, the effect of siMSLN-1 was evaluated
in combination with cisplatin. When the two agents were used in
combination, the growth was completely inhibited (p,0.05, Figure
5A). Moreover, the addition of siMSLN-1 in cultures treated with
imatinib or gemcitabine (each as a single agent) or imatinib+
gemcitabine caused further reductions in proliferation. However,
the effect of siMSLN-1 was not statistically significant, in contrast
to cultures treated with the two chemotherapeutic drugs together
with siCtrl (p = 0.21, p = 0.38, and p=0.17, respectively).
Role of MSLN in cell cycle progression and apoptosis
following treatments with chemotherapeutic drugs
Following flow cytometry analysis, Mero-14 cells treated with
siMSLN-1 in combination with cisplatin or imatinib or gemcita-
bine (each as a single agent) or imatinib+gemcitabine, showed a
statistically significant decreased share of cells in S+G2+M phase,
as compared to their respective cultures where siMSLN-1 were
replaced with siCtrl (Figure 5B). This finding further confirmed
the activity of siMSLN-1 in slowing the progression through cell
cycle.
In treatments where siRNA was combined with chemothera-
peutic drugs, activities of caspases-3 and -7 were measured as
markers for apoptosis. The addition of siMSLN-1 in cultures
treated with imatinib or gemcitabine (each as a single agent) or
imatinib+gemcitabine was not associated with an increased rate of
apoptosis as compared to cultures treated with the chemothera-
Figure 3. Progression of cells through the cell cycle following
flow cytometry analysis. The graph shows the percentage of Mero-
14 cells in phase S+G2+M treated with 40 nM of the siCtrl or siMSLN-1.
The S+G2+M phase of the cell cycle was slightly reduced following the
treatment with siMSLN-1 (*P = 0.033). Error bars represent SEM of six
independent experiments.
doi:10.1371/journal.pone.0085935.g003
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peutic drugs together with siCtrl. Interestingly, a synergistic effect
was observed when cisplatin was used in combination with
siMSLN-1. In fact, siMSLN-1 or cisplatin alone did not induce
apoptosis, whereas they markedly (and in a statistically significant
way) induced increased apoptosis rates when used together (Figure
5C). This observation was further corroborated by the induction of
p53 and by the cleavage of PARP, both additional markers for
apoptosis (Figure 5D). The effect was dose-dependent and visible
from 5 mM of cisplatin.
Discussion
The present work provides evidence on the importance of
MSLN for cell growth and invasiveness in MPM. The transient
MSLN-silencing caused a decrease in the proliferation rate of the
MSLN-overexpressing cell line Mero-14. These data are in
agreement with those observed on PC cells [24]. Similar findings
were also reported by Wang et al. in the MSLN-overexpressing
MPM cell lines H2373 [25]. As with the H2373 MPM cells, the
substantial arrest of the proliferation rate observed in the Mero-14
cells was underlined by the shift of the phosphorylation status of
AKT and ERK (used as a marker of proliferation). The results on
MPM cells were in agreement with the findings observed in PC
and OC cells [25], suggesting that all the MSLN-expressing cancer
cells show a significant loss of viability upon MSLN depletion. In
addition to the reduced proliferation, Mero-14 cells also showed a
reduced capacity of sphere formation in a three-dimensional
context. Concerning the cell cycle, a significant increase (50%) of
MPM H2373 cells in the S-phase was observed portraying a
blockade in progression from S to G2 phase [25]. The results
obtained in Mero-14 cells were different, since a reduction of cells
in S-phase was observed, paralleling an increase of cells in G1
phase. The differences could be ascribed to the different methods
of siRNA administration (electroporation in H2373 versus
chemical transfection in Mero-14) involving different time of
observation (48 versus 72 hours, respectively). However, the
overall decrease of cells in G2/M was consistent in both cell lines.
Moreover, a significant reduction in invasiveness was observed in
both Mero-14 and H2373 cells in the trans-well assay. With regard
to apoptosis, no assays were reported for H2373. In general, MPM
cell lines are quite refractory to undergo apoptosis and this was
also observed in Mero-14 cells after MSLN depletion or a
treatment with cisplatin. By contrast, MSLN silencing was able to
promote apoptosis in PC AsPC-1, Capan-1, and Capan-2 cells
Figure 4. Role of MSLN in cellular migration and invasion. A. No effects observed in the wound-healing assay, following siRNA transfections.
Confluent monolayers of Mero-14 cells transfected with 40 nM of siCtrl, or siMSLN-1, respectively. Two different experiments were carried out, each
performed in triplicate. B. Trans-well cell invasion assay on Mero-14 cells transfected with 40 nM of the siCtrl (top), or siMSLN-1 (bottom). Pictures
were taken using a fluorescence microscope at 10X magnification and are reported as negative of the originals to enhance the contrast between the
background and the DAPI-stained cells. The bar chart shows the average of invasive cells (error bars represent SEM of two independent experiments,
each done in triplicate, *P = 0.0044).
doi:10.1371/journal.pone.0085935.g004
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Figure 5. Role of MSLN in cellular growth, cell cycle progression and apoptosis, following treatment with chemotherapeutic drugs.
A. Proliferation assay in Mero-14 cells. The graph shows the effect of the treatments with 5 mM cisplatin and 40 nM siMSLN-1, used as single agents or
in combination. On day 6, MANOVA shows a statistically significant effect both for cisplatin (P = 0.0168) and siMSLN-1 (P,1024) in reducing
proliferation. However, the interaction term for the effect of both agents in combination is not statistically significant (P = 0.145). Error bars represent
SEM of three independent experiments, each performed in quadruplicate. B. Flow cytometry analysis. The graph shows the percentage of cells in
phase S+G2+M in Mero-14 cells treated with 40 nM of the siCtrl or siMSLN-1 in combination with imatinib (25 mM) or gemcitabine (1 mM) (alone) or
imatinib+gemcitabine (10 mM and 1 mM, respectively). The transfection with siMSLN-1 was accompanied with a marked decrease of cells in S+G2+M
phase, as compared with the respective cultures transfected with siCtrl, irrespectively of the drugs employed (P = 0.00033). Error bars represent SEM
of two independent experiments. C. Caspase activity measured on Mero-14 cells transfected with 40 nM of siCtrl, or siMSLN-1, with or without
cisplatin 5 mM. A marked increase in apoptosis is observed when siMSLN-1 and cisplatin are administered together, compared to cultures treated with
cisplatin and transfected with siCtrl (*P = 0.018), suggesting a synergistic effect. Error bars represent SEM of three independent experiments, each
performed in triplicate. D. Western blotting analysis of MSLN, p53, and PARP under different combinations of siRNAs and cisplatin (at 5, 10 and
20 mM). b-actin was used as reference. The protein levels were confirmed with three independent experiments. Legend to figure 5: Dark line: cells
trated with siCtrl; gray line and triangles: cells treated with siCtrl plus cisplatin; gray line and dark spots: cells treated with siMSLN plus cisplatin; dark
line and white spots: cells treated with siMSLN-1.
doi:10.1371/journal.pone.0085935.g005
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[24]. However, MSLN depletion triggered a marked increase in
apoptosis in Mero-14 cells when used in combination with
cisplatin, thereby suggesting a synergistic effect. In Mero-14 cells,
the activation of caspases-3 and 7 was associated with the
induction of p53 and with the cleavage of PARP, both markers
of a pro-apoptotic activity.
In summary, paralleling previous studies, our findings confirm
that MSLN should not be regarded only as an interesting
diagnostic marker for MPM or a promising target for immuno-
therapies. Despite the limited knowledge on the biological role of
MSLN in normal and cancer cells, MSLN should also be
considered a key molecular target for novel gene-based targeted
therapies of cancer.
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